Adnan Khan, Hussain Saddam, Amir Muhammad, Ahmed Sohail, Akbar Amna, Jadoon Sarosh Khan, Khan Sania, ZiLong Zhang, Saleem Khan Mohammad
Gastrointestinal Surgery, Yangtze University, Jingzhou, CHN.
General Surgery, Zia Darman Hospital, Mardan, PAK.
Cureus. 2024 Apr 17;16(4):e58481. doi: 10.7759/cureus.58481. eCollection 2024 Apr.
Colorectal cancer (CRC) ranks as the second leading cause of cancer-related mortality among women and the third leading cause of cancer-associated mortality among men. Treatment of colon cancer is very crucial for a patient's survival. In this study, we assessed the reliability, efficacy, and safety of raltitrexed in intraoperative intraperitoneal chemotherapy for colon cancer.
A total of 57 patients with clinical stages II and III of colon cancer were included in the study. R0 resection surgery + hyperthermic intraperitoneal chemotherapy (HIPEC) procedure was done with raltitrexed. It was given in a dose of 3 mg/m in a 0.9% NS injection in a volume of 500 milliliters. Postoperative complications were observed.
The most common postoperative complication was nausea/vomiting, which was seen in 21 out of 57 patients (37%). The second most common complication was fever (18/57). None of the patients died or developed renal toxicity, hepatic toxicity, and intestinal obstruction.
Raltitrexed is a reliable, efficient, and safe drug and can be used in intraoperative intraperitoneal chemotherapy of colon cancer.
结直肠癌（CRC）是女性癌症相关死亡的第二大主要原因，也是男性癌症相关死亡的第三大主要原因。结肠癌的治疗对患者的生存至关重要。在本研究中，我们评估了雷替曲塞在结肠癌术中腹腔内化疗中的可靠性、疗效和安全性。
本研究共纳入57例临床II期和III期结肠癌患者。采用雷替曲塞进行R0切除手术+热灌注腹腔化疗（HIPEC）。以3mg/m²的剂量溶于500毫升0.9%的生理盐水注射液中给药。观察术后并发症。
最常见的术后并发症是恶心/呕吐，57例患者中有21例出现（37%）。第二常见的并发症是发热（18/57）。没有患者死亡或出现肾毒性、肝毒性和肠梗阻。
雷替曲塞是一种可靠、有效且安全的药物，可用于结肠癌的术中腹腔内化疗。
